Ever since Adamis Pharmaceuticals (NASDAQ:ADMP) announced earlier on this month that the National Institute of Health identified its experimental medicine Tempol as a potential treatment for COVID 19, the stock has been in focus.
Over the course of the past month, the stock has soared by 35% and has emerged as a stock that could be followed closely by investors. The company had announced that the NIH conducted a cell structures study and it was found the Tempol could limit COVID 19 infection.
However, that is not all. The company got a boost recently in relation to its product Zimhi, which is meant for treating opioid overdose. The company announced that its resubmission for a new drug application for Zimhi was accepted by the United States Food and Drug Administration. The company revealed that the agency judged the new application to be sufficiently complete so as to deserve a review. These two notable developments have been primary reasons behind the optimism about the Adamis stock.
Technical Indicators
| Symbol | Value | Result | Symbol | Value | Result |
| ADX | 23.5051 | Neutral | ATR14 | 0.1244 | |
| CCI20 | 73.3328 | Buy | Chaikin Money Flow | 0.1164 | Buy |
| MACD | 0.0639 | Buy | Money Flow Index | 71.5806 | Sell |
| ROC | 50.6424 | Buy | RSI | 59.1059 | Sell |
| STOCH (14,3) | 61.1511 | Sell | STOCH RSI | 0.1831 | OverSold |
| UO | 39.9324 | Sell | Williams %R | -38.8489 | Neutral |
Pivot Points
| Name | S3 | S2 | S1 | Pivot Points | R1 | R2 | R3 |
| Classic | 0.9568 | 0.9735 | 0.9967 | 1.0134 | 1.0366 | 1.0533 | 1.0765 |
| Fibonacci | 0.9735 | 0.9887 | 0.9981 | 1.0134 | 1.0286 | 1.0380 | 1.0533 |
 Up 35% in a Month:Break Out Ahead?){kind=link}